Valuation: Immunovia AB

Market Cap 4.34Cr 43.45L 38.6L 36.12L 32.73L 61.75L 42Cr 62.26L 1.69Cr 21Cr 1.63Cr 1.6Cr 69Cr P/E 2026 *
-0.65x
P/E 2027 * -1.61x
Enterprise Value 83.87L 8L 7L 7L 6L 11.94L 8.1Cr 12.04L 32.6L 4.13Cr 31.54L 30.86L 13Cr EV / Sales 2026 *
2.62x
EV / Sales 2027 * 0.77x
Free-Float
90.23%
Yield 2026 *
-
Yield 2027 * -
1 day-32.03%
1 week+20,654.23%
Current month+32,638.46%
1 month+24,682.61%
3 months+16,370.59%
6 months+17,042.86%
Current year+13,658.62%
1 month 0.1
Extreme 0.0975
0.32
Current year 0.1
Extreme 0.0975
0.32
1 year 0.1
Extreme 0.0975
0.35
3 years 0.1
Extreme 0.0975
2.78
5 years 0.1
Extreme 0.0975
131.5
10 years 0.1
Extreme 0.0975
292
Manager TitleAgeSince
Chief Executive Officer 53 29/04/2023
Chief Tech/Sci/R&D Officer 55 29/04/2024
Chief Tech/Sci/R&D Officer 54 31/01/2024
Director TitleAgeSince
Director/Board Member 72 09/12/2016
Chairman 70 26/05/2023
Director/Board Member 51 01/01/2021
Change 5-day change 1-year change 3-year change Capi.($)
-32.03%+20,654.23% - - 47.62L
-2.98%-3.24%+20.85%+31.84% 25TCr
-2.53%-5.16%+0.29%-0.58% 16TCr
-0.42%-2.42%-10.52%+39.53% 14TCr
-0.50%-4.35%-56.65%-18.36% 6.14TCr
-0.86%-0.40%+12.21%+19.78% 5.03TCr
+1.66%-1.55%-20.09%-20.26% 4.67TCr
-1.00%-3.36%+19.55%+53.45% 4.83TCr
+0.02%+1.26%-4.31%+40.76% 4.59TCr
-0.84%-1.47%+32.90%+64.08% 4.32TCr
Average -3.88%-2.32%-0.64%+23.36% 9.39TCr
Weighted average by Cap. -1.39%-2.77%+2.50%+23.30%

Financials

2026 *2027 *
Net sales 32L 3L 3L 3L 2L 5L 3.09Cr 5L 12.44L 1.58Cr 12.03L 11.77L 5.11Cr 1.73Cr 17.32L 15.39L 14.4L 13.05L 24.62L 17Cr 24.83L 67.24L 8.52Cr 65.05L 63.65L 28Cr
Net income -8.7Cr -87.12L -77.4L -72.43L -65.64L -1.24Cr -84Cr -1.25Cr -3.38Cr -43Cr -3.27Cr -3.2Cr -138.84Cr -7.6Cr -76.11L -67.62L -63.27L -57.34L -1.08Cr -73Cr -1.09Cr -2.95Cr -37Cr -2.86Cr -2.8Cr -121.29Cr
Net Debt -3.5Cr -35.05L -31.14L -29.14L -26.41L -49.81L -34Cr -50.23L -1.36Cr -17Cr -1.32Cr -1.29Cr -56Cr -3Cr -30.04L -26.69L -24.97L -22.63L -42.69L -29Cr -43.05L -1.17Cr -15Cr -1.13Cr -1.1Cr -48Cr
Projected Income Statement - Annual - Immunovia AB
Logo Immunovia AB
Immunovia AB (publ) is a Sweden-based diagnostic company that is developing and commercializing blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s test platform called IMMray. Tests are based on antibody biomarker microarray analysis using machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a disease biomarker signature. Immunovia Dx Laboratories locations in USA and Sweden provides laboratory testing services in two accredited reference laboratories.
Employees
18
Date Price Change Volume

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Immunovia AB